Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidance for salmonella in peanut products

This article was originally published in The Tan Sheet

Executive Summary

FDA issues guidance to assist manufacturers of products containing peanut ingredients in avoiding contamination by salmonella bacteria. The March 11 guidance advises firms to "obtain peanut-derived product only from suppliers with validated processes in place to adequately reduce the presence of salmonella." FDA suggests companies not rely on a history of negative microbiological tests for salmonella in finished peanut product, as this does not ensure the adequacy of a supplier's procedures for controlling bacteria. Peanut-containing products recalled recently in the salmonella outbreak include nutritional bars, though industry experts say dietary supplement ingredients generally do not harbor harmful bacteria (1"The Tan Sheet" Jan. 26, 2009, p. 8)

You may also be interested in...

Salmonella guidance

FDA publishes draft guidance addressing the risk of salmonella contamination in pistachio-derived ingredients. The agency will accept comments on the guidance until Aug. 28, according to a June 29 Federal Register notice. FDA published a guidance on avoiding salmonella contamination of peanut products in March (1"The Tan Sheet" March 16, 2009, In Brief)

Supplements Shielded From Spread Of Peanut Butter-Like Problems – Trades

Safeguards in place in the dietary supplement industry would prevent or quickly contain a crisis like the current spate of recalls of peanut butter-containing products now facing the food industry, supplement experts say

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts